HC Wainwright Issues Negative Estimate for PCRX Earnings

Posted by Geri Gentry on Aug 12th, 2026

Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) – Equities research analysts at HC Wainwright decreased their Q3 2026 earnings estimates for Pacira BioSciences in a research note issued on Wednesday, August 5th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of $0.47 for the quarter, down from their previous estimate of $0.48. HC Wainwright currently has a “Buy” rating and a $38.00 price objective on the stock. The consensus estimate for Pacira BioSciences’ current full-year earnings is $1.94 per share. HC Wainwright also issued estimates for Pacira BioSciences’ FY2026 earnings at $1.88 EPS, Q1 2027 earnings at $0.38 EPS, Q2 2027 earnings at $0.31 EPS, Q3 2027 earnings at $0.64 EPS, Q4 2027 earnings at $0.66 EPS and FY2027 earnings at $1.99 EPS.

Pacira BioSciences (NASDAQ:PCRX – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.08. Pacira BioSciences had a net margin of 1.96% and a return on equity of 9.68%. The firm had revenue of $192.40 million during the quarter, compared to analyst estimates of $191.06 million. During the same period in the previous year, the business posted $0.74 EPS. The business’s quarterly revenue was up 6.2% on a year-over-year basis.

Several other research firms also recently weighed in on PCRX. Wall Street Zen raised shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings upgraded Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, May 20th. Needham & Company LLC boosted their target price on Pacira BioSciences from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Royal Bank Of Canada boosted their target price on Pacira BioSciences from $24.00 to $25.00 and gave the company a “sector perform” rating in a research note on Wednesday, August 5th. Three equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Pacira BioSciences has a consensus rating of “Hold” and an average price target of $29.80.

Get Our Latest Report on PCRX

Pacira BioSciences Price Performance

PCRX stock opened at $24.38 on Wednesday. The firm has a market cap of $971.79 million, a P/E ratio of 69.66 and a beta of 0.27. The firm’s fifty day moving average is $24.76 and its 200 day moving average is $23.50. Pacira BioSciences has a 52 week low of $18.80 and a 52 week high of $27.66. The company has a debt-to-equity ratio of 0.54, a quick ratio of 3.94 and a current ratio of 5.04.

Insider Activity at Pacira BioSciences

In related news, SVP Lauren Riker sold 6,115 shares of Pacira BioSciences stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $23.50, for a total value of $143,702.50. Following the transaction, the senior vice president directly owned 62,284 shares of the company’s stock, valued at $1,463,674. The trade was a 8.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Pacira BioSciences

A number of hedge funds have recently modified their holdings of PCRX. Impax Asset Management Group plc boosted its holdings in shares of Pacira BioSciences by 25.0% during the fourth quarter. Impax Asset Management Group plc now owns 750,027 shares of the company’s stock worth $19,411,000 after purchasing an additional 150,000 shares during the period. Hillsdale Investment Management Inc. purchased a new position in shares of Pacira BioSciences during the fourth quarter valued at approximately $7,976,000. LSV Asset Management increased its position in Pacira BioSciences by 179.8% during the 4th quarter. LSV Asset Management now owns 319,800 shares of the company’s stock valued at $8,276,000 after purchasing an additional 205,500 shares during the period. Gagnon Advisors LLC lifted its position in shares of Pacira BioSciences by 22.3% in the 4th quarter. Gagnon Advisors LLC now owns 260,908 shares of the company’s stock worth $6,752,000 after purchasing an additional 47,506 shares during the period. Finally, Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in shares of Pacira BioSciences by 360.1% during the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 69,097 shares of the company’s stock valued at $1,788,000 after purchasing an additional 54,079 shares in the last quarter. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences News Summary

Here are the key news stories impacting Pacira BioSciences this week:

Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to $1.88 from $1.73 and increased its Q4 2026 estimate to $0.68 from $0.64. These revisions suggest improved near-term earnings expectations for Pacira BioSciences.
Positive Sentiment: The firm continues to project earnings growth into 2027, including estimates of $0.38 EPS for Q1, $0.31 for Q2, $0.64 for Q3 and $0.66 for Q4. Its $38 price target implies substantial potential upside if those forecasts are achieved.
Positive Sentiment: A recent article examines whether Pacira is reframing its non-opioid pain-management strategy around PCRX-201 gene therapy, potentially highlighting a longer-term growth opportunity beyond its existing products. Is Pacira BioSciences Quietly Reframing Its Non-Opioid Strategy Around PCRX-201 Gene Therapy?
Neutral Sentiment: HC Wainwright’s estimates for Q1–Q4 2027 imply FY2027 EPS of $1.99, compared with the current consensus estimate of $1.94, while its Buy rating remains unchanged.
Negative Sentiment: HC Wainwright lowered its Q3 2026 EPS estimate slightly to $0.47 from $0.48 and cut its FY2027 forecast to $1.99 from $2.29. The sizable long-term reduction may weigh on sentiment despite the higher FY2026 outlook.
Neutral Sentiment: Reported short interest was listed at zero shares with a zero-day days-to-cover ratio. Because the figures appear inconsistent with normal market data, they provide little useful signal for PCRX investors.

About Pacira BioSciences

(Get Free Report)

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.